Catalyst Biosciences To Present at the Jefferies 2016 Complement Therapeutics Summit
May 02 2016 - 8:28AM
Catalyst Biosciences, Inc. (NASDAQ:CBIO), a leading biotechnology
company focused on discovering and developing novel protease
therapeutics for the treatment of serious medical conditions in the
fields of hemostasis and anti-complement, today announced that
Nassim Usman, Ph.D., President and Chief Executive Officer, will
present at the Jefferies 2016 Complement Therapeutics Summit on
Tuesday, May 3, 2016 at 9:00 a.m. E.T. The conference is being held
at the Jefferies Conference Center in New York City.
About Catalyst Biosciences Catalyst is a
clinical-stage biopharmaceutical company focused on creating and
developing novel medicines to address serious medical conditions.
To date, Catalyst has focused its product development efforts in
the fields of hemostasis, including the treatment of hemophilia and
surgical bleeding, and inflammation, including prevention of
delayed graft function in renal transplants and the treatment of
dry age-related macular degeneration, a condition that can cause
visual impairment or blindness. Catalyst’s most advanced program is
an improved next-generation coagulation Factor VIIa variant, CB
813d, which has successfully completed a Phase 1 clinical trial in
severe hemophilia A and B patients. In addition to Catalyst’s lead
Factor VIIa program, Catalyst has two other next-generation
coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is
in advanced preclinical development, and a Factor Xa variant, that
is in the advanced lead stage of development. For more information,
please visit www.catalystbiosciences.com.
Contacts:
Investors:
Fletcher Payne, CFO
Catalyst Biosciences, Inc.
650.871.0761
investors@catbio.com
Media:
Denise Powell
Red House Consulting, LLC
510.703.9491
denise@redhousecomms.com
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024